Development of an automated liquid biopsy assay for methylated markers in advanced breast cancer.
Automated
Biomarker
Breast Cancer
DNA Methylation
Liquid Biopsy
Journal
Cancer research communications
ISSN: 2767-9764
Titre abrégé: Cancer Res Commun
Pays: United States
ID NLM: 9918281580506676
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
entrez:
1
9
2022
pubmed:
2
9
2022
medline:
2
9
2022
Statut:
ppublish
Résumé
Current molecular liquid biopsy assays to detect recurrence or monitor response to treatment require sophisticated technology, highly trained personnel, and a turnaround time of weeks. We describe the development and technical validation of an automated Liquid Biopsy for Breast Cancer Methylation (LBx-BCM) prototype, a DNA methylation detection cartridge assay that is simple to perform and quantitatively detects nine methylated markers within 4.5 h. LBx-BCM demonstrated high interassay reproducibility when analyzing exogenous methylated DNA (75-300 DNA copies) spiked into plasma (Coefficient of Variation, CV = 7.1 - 10.9%) and serum (CV = 19.1 - 36.1%). It also demonstrated high interuser reproducibility (Spearman
Identifiants
pubmed: 36046124
doi: 10.1158/2767-9764.crc-22-0133
pmc: PMC9426415
mid: NIHMS1807270
doi:
Substances chimiques
DNA
9007-49-2
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
391-401Subventions
Organisme : NCI NIH HHS
ID : P50 CA088843
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA103175
Pays : United States
Références
Clin Genet. 2019 Jun;95(6):643-660
pubmed: 30671931
Sci Rep. 2021 Dec 15;11(1):24041
pubmed: 34911971
Pharmacogenomics. 2020 Apr;21(5):359-367
pubmed: 32284011
Cells. 2020 Mar 05;9(3):
pubmed: 32150897
Front Genet. 2019 Jun 28;10:621
pubmed: 31316555
Clin Chem. 2017 Aug;63(8):1370-1376
pubmed: 28615231
Cell. 2018 Nov 15;175(5):1244-1258.e26
pubmed: 30454645
Clin Breast Cancer. 2020 Dec;20(6):e711-e722
pubmed: 32792225
Breast Cancer Res Treat. 2018 Nov;172(2):327-338
pubmed: 30120700
Cancer Prev Res (Phila). 2016 Aug;9(8):673-682
pubmed: 27261491
Ann Oncol. 2021 Sep;32(9):1167-1177
pubmed: 34176681
ESMO Open. 2022 Apr;7(2):100399
pubmed: 35202954
Clin Epigenetics. 2020 Jul 6;12(1):100
pubmed: 32631437
Front Genet. 2019 Nov 14;10:1150
pubmed: 31803237
J Clin Oncol. 2017 Mar;35(7):751-758
pubmed: 27870562
Clin Cancer Res. 2016 Feb 15;22(4):993-9
pubmed: 26261103
Cancers (Basel). 2022 Mar 03;14(5):
pubmed: 35267616
Mol Oncol. 2015 Mar;9(3):555-68
pubmed: 25468711
Oncotarget. 2016 Apr 5;7(14):18485-94
pubmed: 26918343
J Immunother Cancer. 2019 Sep 18;7(1):254
pubmed: 31533832
Clin Cancer Res. 2019 Nov 1;25(21):6357-6367
pubmed: 31300453
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
PLoS One. 2017 Mar 9;12(3):e0173532
pubmed: 28278193
Br J Cancer. 2009 Nov 3;101(9):1522-8
pubmed: 19861999
Surg Pathol Clin. 2022 Mar;15(1):105-120
pubmed: 35236627
Nature. 2018 Nov;563(7732):579-583
pubmed: 30429608
Cancer Res. 2014 Apr 15;74(8):2160-70
pubmed: 24737128